OAM
SLS icon

Oxford Asset Management’s SELLAS Life Sciences SLS Stock Holding History

Oxford Asset Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,501
Closed -$150K – 600
2026
Q1 		$150K Buy
+35,501
New +$159K 0.06% 401
2020
Q1 		– Sell
-41,285
Closed -$178K – 1130
2019
Q4 		$178K Buy
+41,285
New +$222K ﹤0.01% 1567
2019
Q1 		– Sell
-1,169
Closed -$72K – 1952
2018
Q4 		$72K Buy
+1,169
New +$90.5K ﹤0.01% 1675

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Oxford Asset Management's SLS Position: Q2 2026 in Review

Oxford Asset Management sold out of SELLAS Life Sciences (SLS) in Q2 2026, closing a stake of 35,501 shares — an estimated $150K sold.

Oxford Asset Management first reported a position in SLS in Q4 2018 and held it in 3 quarters. The position peaked at $178K in Q4 2019. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Oxford Asset Management reported no remaining SELLAS Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Oxford Asset Management sold 35,501 SELLAS Life Sciences shares in Q2 2026, an estimated $150K.
  • Oxford Asset Management first reported a position in SELLAS Life Sciences in Q4 2018 and held it in 3 quarters.
  • Oxford Asset Management's SELLAS Life Sciences position peaked at $178K in Q4 2019.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.